Trials / Unknown
UnknownNCT05803746
PD-L2 Targeting Nanobody Radiotracer for PET Imaging of Solid Tumor
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The objective of this study is to construct a noninvasive approach using 68Ga- Mirc415 PET/CT to detect the PD-L2 expression of tumor lesion in patients with colorectal cancer, lung cancer and other solid tumor to identify patients benefiting from anti-PD-(L)1 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-FDG | All study participants will undergo one 18F-FDG PET/ CT scan. |
Timeline
- Start date
- 2022-07-15
- Primary completion
- 2024-07-15
- Completion
- 2024-07-15
- First posted
- 2023-04-07
- Last updated
- 2023-04-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05803746. Inclusion in this directory is not an endorsement.